Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. - Wikidata - awgldk - TriplyDB

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q43904556

about

Fifty years of melphalan use in hematopoietic stem cell transplantation Practical management of classical myeloproliferative disorder patients: a clinician's guide Mesenchymal stem cells and bone regeneration Thalidomide for the treatment of idiopathic myelofibrosis.Modern management of myelofibrosis.Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Outcome of transplantation for myelofibrosis.Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Choosing between stem cell therapy and drugs in myelofibrosis.Adoptive cellular therapy: a therapeutic reality?Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.How to manage the transplant question in myelofibrosis.Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.The graft-versus-lymphoma effect: clinical review and future opportunities.Role of GATA-1 in normal and neoplastic hemopoiesis.Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Morphology of the bone marrow after stem cell transplantation.Allogeneic stem cell transplantation as treatment for myelofibrosis.Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.Myelofibrosis: biology and treatment options.Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.Allogeneic hematopoietic cell transplantation for patients with myelofibrosis Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.Allogeneic stem cell transplantation for myelofibrosis in 2012.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Myelofibrosis: an update on current pharmacotherapy and future directions.The significance of cytomegalovirus viremia at day 100 or more following allogeneic hematopoietic stem cell transplantation.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Treatment of blood flow abnormality using mucosal delivery of nitric oxide.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience.The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.Fatal hepatic failure associated with graft rejection following reduced-intensity stem-cell transplantation for chronic idiopathic myelofibrosis (CIMF).

P2860

Q26824498-344A514E-A9A6-40F5-9BB6-E7E5208FCEFC Q28200207-605586C7-CDA2-4391-ABFB-1226BE2DD2E6 Q28236319-405846FE-ECDC-4190-8643-475AEC7BACEE Q33359542-115A9C2B-560B-444A-A9DA-39543C25D616 Q33365122-884436C1-BB0E-4651-9BD5-9EC0544A3394 Q33517074-941D5EF8-03D1-4F33-B4DF-7A6AA8B6B5D3 Q33556843-B5DF35A7-A3C5-4630-B543-377B3B1BF35D Q33771667-A4538794-3B5C-4801-A001-F3894645EDA5 Q34015474-1703C39F-03D2-495D-B6AD-59F1ABF1E072 Q34625390-5FD42CD3-7DD3-49A0-9096-A5B3E10F5C29 Q34734491-BFD47A87-A072-4FAA-93A9-9E83BBC45DB3 Q34875170-7EFA332E-F09D-4992-ACFF-F79172E8BD93 Q35196663-BD7B2D15-C7F3-440C-85D1-0FC4D2C1EDE1 Q35608022-710A8C03-D22B-4726-8E8A-2B69A8EA921E Q35865676-3F1AE0ED-9555-4456-837C-AA3C7D111207 Q35901696-7B89B9F7-1D15-45CF-A13F-C227224FD86C Q36128232-A0A32539-7A1C-400E-B580-D39A68C31EA4 Q36164515-DD84844F-900B-4CB9-8805-9ECC0FF3F1A3 Q36182976-4EE61B93-7BD8-4B7E-B562-4A59ED5BD7FD Q36399935-5288EA8D-1D19-45EE-B938-75736F2936FC Q36609417-20631010-0308-4539-B998-0C68FCF7619E Q36741655-22A3B9E2-A413-4E04-A273-32120BA68256 Q36922494-32FF1B2B-2EE2-4527-AA0D-E48D75642B4D Q37353939-A0B0E3AC-15C0-44CB-B17E-4D774C992B78 Q37495397-86A5768E-7C59-4661-813A-867E82509736 Q37521161-0E1BFF4F-7D30-4CDE-B1C0-DAC1E2787FC0 Q37998567-79D195A2-8C21-4954-8C0B-D44BC5323421 Q38018908-EA001409-8F27-4AEA-9893-702B55AE16EA Q38091447-8A190FDD-FE28-4A91-A7CA-061A78BDFEB5 Q38102060-136C3AC0-B62C-45DF-ACA2-26F887E28F17 Q38349213-9EF03F04-EFF4-4BA9-AFA2-FFC80B484BD2 Q38383428-703F1764-5B00-48FA-A6DC-8F190DEF4643 Q38569146-476967FE-4A89-4755-B5A1-838F179C02FA Q38603384-1E9589B1-A50F-4A45-B18B-E3BD8F1ADE8E Q40829969-CBFAE206-046E-4B0E-9ACD-2B067AA7DAD0 Q42201127-0A31B5E7-E3F7-4A59-A142-125111E48BD8 Q42588904-1BB3362E-6132-4E78-9CF9-0609FDB9EB50 Q43162409-A23D1A85-E258-4037-A2F8-730D1E23889E Q44220338-D69EA3EE-AF69-4C8B-B88F-E72B4EE39537 Q45204139-2FCE9F2B-06D3-4FD9-8854-F0D3050667C2

P2860

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q43904556

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@en

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@nl

type

label

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@en

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@nl

prefLabel

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@en

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@nl

P1433

Q43904556-3CDFA6B2-BC3A-489E-B6FF-F86196AD2FB8

P1476

Q43904556-C51CB88A-69F3-4DA6-BD8F-8A15B35A03C8

P2093

Q43904556-06342D01-D8B8-45A1-A50F-9BD22E0652CF

Q43904556-4782A285-790B-4E85-B28E-CFA2A35178BA

Q43904556-4A2F4089-3626-4A92-8DF1-8805074DEEF7

Q43904556-5405E6CD-ADA0-4107-B4EB-F80D63AA7C0E

Q43904556-7FE80575-703D-40A2-B417-757CCF9203CC

Q43904556-83CB2C3B-68BD-4C4B-A191-EBCFE66B5A82

Q43904556-95CFBC73-B8C5-4B68-878D-05A640004157

Q43904556-9CB5A195-0C5C-4B8E-94C1-1B71F2D61486

Q43904556-AD94EB8C-EA3B-4782-9070-7DEBA5C13AEF

Q43904556-CA45AE46-653F-4D7A-A80A-B81328F08E87

P304

Q43904556-BB301C44-0D63-492E-A165-498B56AE5D6A

P31

Q43904556-541F104C-7726-4EA4-8593-3510932578AB

P356

Q43904556-D97DD53F-3C5B-4ADD-809B-2D2FC94720C3

P407

Q43904556-40FC2B0F-1425-4740-BE1D-45C50E1AB5DE

P433

Q43904556-50C1AAD2-7435-40BF-A568-08DA548B53F9

P478

Q43904556-66F80B78-725A-439C-BC7B-ECBCF21D4D85

P50

Q43904556-6F1FAB66-59A8-4F40-8025-36366C2BFACE

P577

Q43904556-FB96680A-25B8-448F-982F-7AF7C0ED96AA

P698

Q43904556-2A86E81B-048E-4CF3-8BD6-9181BFEFFB2E

P356

BLOOD.V99.6.2255

P1433

P1476

Allogeneic blood cell transpla ...... rosis with myeloid metaplasia.

@en

P2093

Amit Verma

http://www.w3.org/2001/XMLSchema#string

Basil A Bradlow

http://www.w3.org/2001/XMLSchema#string

David Peace

http://www.w3.org/2001/XMLSchema#string

Deana Thomason

http://www.w3.org/2001/XMLSchema#string

Ellen Jessop

http://www.w3.org/2001/XMLSchema#string

Marianne Huml

http://www.w3.org/2001/XMLSchema#string

Rajul Shah

http://www.w3.org/2001/XMLSchema#string

Ron Hoffman

http://www.w3.org/2001/XMLSchema#string

Steven M Devine

http://www.w3.org/2001/XMLSchema#string

Vera Maynard

http://www.w3.org/2001/XMLSchema#string

P304

2255-2258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V99.6.2255

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Koen van Besien

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11877308

http://www.w3.org/2001/XMLSchema#string